Collaboration to develop a cancer therapy to be used with immune checkpoint inhibitors
Bristol-Myers Squibb and Nektar Therapeutics are working together to develop a cancer therapy [...]
Promising new immunotherapy drug for advanced/metastatic kidney cancer
Immunotherapy has revolutionised the treatment of renal cell carcinoma (RCC). [...]
New insights into immune-related adverse events in genitourinary cancers
The following is an interview with Dr Tanya Dorff, Associate Clinical [...]
Potential role for high dose IL2 in metastatic kidney cancer
The following is an interview with Dr Tanya Dorff, Associate Clinical [...]
First-line immunotherapy for metastatic kidney cancer
The following is a Practice Update interview with Dr Eric [...]
Managing adverse events for cancer immunotherapies
Immunotherapy treatments for cancer hold great promise, but also come [...]
Status of adjuvant therapy for the treatment of kidney cancer
Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an [...]
Tyrosine kinase inhibitors for kidney cancer: Past, present and future
In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]
The future of immuno-oncology in kidney cancer
In his keynote lecture at the American Society for Clinical [...]
Axitinib plus pembrolizumab combination shows promise for advanced kidney cancer
Data from a recent phase 1b study has shown that [...]
